10-K/A - Longevity Health Holdings, Inc. (0001842939) (Filer)

Tue, Jun 17, 9:02 PM (26 days ago)

### Summary of Longevity Health Holdings, Inc. (XAGE) **Financial Performance:** - **Revenue:** $90,829,000 in 2024, up from $0 in 2023. - **Net Income:** $(10,368,261,000) in 2024, compared to $(15,445,087,000) in 2023. - **Operating Expenses:** $5,042,459,000 in 2024, down from $5,943,556,000 in 2023. - **Earnings per Share:** $(0.49) in 2024, compared to $(1.46) in 2023. **Strategic Overview:** - **Product Portfolio:** Focus on longevity and healthy aging, with two cosmetic product lines: Carmell Secretome™ and Elevai Exosomes™. - **Recent Developments:** Completed a private placement raising $1,851,849,000 and acquired Elevai, which had $2,500,000 in sales in 2024. - **Market Position:** The skincare and haircare markets are growing, with the aesthetics market growing faster than pharmaceuticals. **Future Outlook:** - **Growth Plans:** Expect to grow revenue from the Elevai acquisition and other cosmetic products. - **Risk Factors:** Includes limited experience as a commercial company, competition, regulatory risks, and financial condition. **Financial Condition:** - **Cash Position:** $157,139,000 in cash as of December 31, 2024. - **Debt:** $241,158,000 in outstanding debt as of December 31, 2024. **Market Position Changes:** - **Nasdaq Listing:** Received notices for not meeting minimum bid price and market value of listed securities requirements. Appealed the delisting determination. **Risk Factors:** - **Operational Risks:** Includes supply chain disruptions, regulatory changes, and competition. - **Financial Risks:** Includes the need for additional capital and the impact of economic conditions. **Amendment Details:** - **Changes:** The amendment corrects the certifications of the Company’s principal executive officer and principal financial officer to correct the Company’s name therein and files a consent of the Company’s independent registered public accounting firm.